Symbols / OLMA
OLMA Chart
About
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.98B |
| Enterprise Value | 1.37B | Income | -149.96M | Sales | — |
| Book/sh | 4.48 | Cash/sh | 4.79 | Dividend Yield | — |
| Payout | 0.00% | Employees | 122 | IPO | — |
| P/E | — | Forward P/E | -10.69 | PEG | — |
| P/S | — | P/B | 5.51 | P/C | — |
| EV/EBITDA | -8.57 | EV/Sales | — | Quick Ratio | 7.97 |
| Current Ratio | 8.03 | Debt/Eq | 1.46 | LT Debt/Eq | — |
| EPS (ttm) | -1.76 | EPS next Y | -2.31 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-24 | ROA | -34.41% |
| ROE | -59.23% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 80.16M |
| Shs Float | 55.33M | Short Float | 13.68% | Short Ratio | 8.67 |
| Short Interest | — | 52W High | 36.26 | 52W Low | 2.86 |
| Beta | 1.92 | Avg Volume | 1.95M | Volume | 1.61M |
| Target Price | $46.09 | Recom | Strong_buy | Prev Close | $24.36 |
| Price | $24.69 | Change | 1.35% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$46.09
Mean price target
2. Current target
$24.69
Latest analyst target
3. DCF / Fair value
$-16.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$24.69
Low
$38.00
High
$60.00
Mean
$46.09
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-11 | init | Stifel | — → Buy | $48 |
| 2026-01-07 | init | UBS | — → Buy | $45 |
| 2026-01-07 | init | Piper Sandler | — → Overweight | — |
| 2025-12-12 | main | Citigroup | Buy → Buy | $60 |
| 2025-12-11 | main | Oppenheimer | Outperform → Outperform | $48 |
| 2025-12-11 | main | Goldman Sachs | Buy → Buy | $38 |
| 2025-12-11 | main | HC Wainwright & Co. | Buy → Buy | $45 |
| 2025-11-21 | main | Goldman Sachs | Buy → Buy | $26 |
| 2025-11-18 | main | Oppenheimer | Outperform → Outperform | $45 |
| 2025-11-18 | main | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-11-18 | main | JP Morgan | Overweight → Overweight | $32 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2025-10-08 | init | Guggenheim | — → Buy | $20 |
| 2025-09-03 | main | Oppenheimer | Outperform → Outperform | $22 |
| 2025-08-14 | main | JP Morgan | Overweight → Overweight | $29 |
| 2025-08-12 | main | Citigroup | Buy → Buy | $21 |
| 2025-05-14 | main | Goldman Sachs | Buy → Buy | $18 |
| 2025-05-14 | main | Oppenheimer | Outperform → Outperform | $22 |
| 2025-04-28 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-03-28 | main | JP Morgan | Overweight → Overweight | $28 |
- Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here? - Yahoo Finance Wed, 19 Nov 2025 08
- Olema Pharmaceuticals Stock (OLMA) Opinions on Strategic Collaboration Announcement | OLMA Stock News - Quiver Quantitative ue, 18 Nov 2025 08
- OLMA May 15th Options Begin Trading - Nasdaq Fri, 30 Jan 2026 08
- Olema Oncology (Nasdaq: OLMA) Completes $218.5M Equity Sale at $19 Per Share - Stock Titan hu, 20 Nov 2025 08
- Candriam S.C.A. Increases Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat Wed, 11 Feb 2026 08
- Stifel initiates coverage on Olema Pharmaceuticals (OLMA) with buy rating - MSN Wed, 18 Feb 2026 00
- OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results - Stocktwits ue, 18 Nov 2025 08
- Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After A 348% One‑Year Surge? - Yahoo Finance ue, 17 Feb 2026 18
- $OLMA stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Wed, 10 Dec 2025 08
- Olema Oncology (Nasdaq: OLMA) prices $190M public offering of 10M common shares - Stock Titan Wed, 19 Nov 2025 08
- Olema Pharmaceuticals (OLMA): Evaluating the Current Valuation After a Strong Run-Up in Recent Months - Yahoo Finance Sun, 23 Nov 2025 08
- $OLMA stock is up 208% today. Here's what we see in our data. - Quiver Quantitative ue, 18 Nov 2025 08
- Breast cancer-focused Olema sees financial officer depart, CEO steps in - Stock Titan Fri, 30 Jan 2026 08
- Olema Pharmaceuticals Closes $218.5 Million Public Offering of Common Stock - Quiver Quantitative hu, 20 Nov 2025 08
- Olema Oncology (Nasdaq: OLMA) Plans Common Stock, Pre-Funded Warrant Offering - Stock Titan ue, 18 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11700 | — | — | Stock Award(Grant) at price 0.00 per share. | AUSTIN SASHA LU | Officer | — | 2026-02-02 00:00:00 | D |
| 1 | 10000 | 268800 | — | Sale at price 26.88 per share. | HARMON CYRUS | Director | — | 2026-01-20 00:00:00 | D |
| 2 | 103822 | 2980054 | — | Sale at price 28.01 - 28.73 per share. | KOVACS SHANE WILLIAM CHARLES | Chief Operating Officer | — | 2026-01-15 00:00:00 | D |
| 3 | 3489 | 101600 | — | Sale at price 29.12 per share. | HARMON CYRUS | Director | — | 2026-01-14 00:00:00 | D |
| 4 | 110000 | 3107229 | — | Sale at price 27.60 - 28.99 per share. | MYLES DAVID C | Officer | — | 2026-01-14 00:00:00 | D/I |
| 5 | 100000 | 487000 | — | Conversion of Exercise of derivative security at price 4.87 per share. | MYLES DAVID C | Officer | — | 2026-01-14 00:00:00 | D |
| 6 | 8500 | — | — | Stock Gift at price 0.00 per share. | BOHEN SEAN | Chief Executive Officer | — | 2025-12-26 00:00:00 | D |
| 7 | 269509 | 7530148 | — | Sale at price 27.66 - 28.93 per share. | ZOJWALLA NASEEM M.D. | Officer | — | 2025-12-23 00:00:00 | D |
| 8 | 140000 | 1664392 | — | Conversion of Exercise of derivative security at price 7.02 - 15.25 per share. | ZOJWALLA NASEEM M.D. | Officer | — | 2025-12-23 00:00:00 | D |
| 9 | 2881 | 82195 | — | Sale at price 28.53 per share. | HARMON CYRUS | Director | — | 2025-12-22 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -141.87M | -104.58M | -106.63M | -71.33M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -129.47M | -96.66M | -104.79M | -71.10M |
| ReconciledDepreciation | 393.00K | 377.00K | 357.00K | 163.00K |
| EBITDA | -141.87M | -104.58M | -106.63M | -71.33M |
| EBIT | -142.26M | -104.96M | -106.99M | -71.49M |
| NetInterestIncome | 12.68M | 8.32M | 2.23M | 442.00K |
| InterestExpense | 0.00 | |||
| InterestIncome | 12.68M | 8.32M | 2.23M | 442.00K |
| NormalizedIncome | -129.47M | -96.66M | -104.79M | -71.10M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -129.47M | -96.66M | -104.79M | -71.10M |
| TotalExpenses | 142.26M | 104.96M | 106.99M | 71.49M |
| TotalOperatingIncomeAsReported | -142.26M | -104.96M | -106.99M | -71.49M |
| DilutedAverageShares | 58.74M | 45.25M | 40.00M | 39.52M |
| BasicAverageShares | 58.74M | 45.25M | 40.00M | 39.52M |
| DilutedEPS | -2.20 | -2.14 | -2.62 | -1.80 |
| BasicEPS | -2.20 | -2.14 | -2.62 | -1.80 |
| DilutedNIAvailtoComStockholders | -129.47M | -96.66M | -104.79M | -71.10M |
| NetIncomeCommonStockholders | -129.47M | -96.66M | -104.79M | -71.10M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -129.47M | -96.66M | -104.79M | -71.10M |
| NetIncomeIncludingNoncontrollingInterests | -129.47M | -96.66M | -104.79M | -71.10M |
| NetIncomeContinuousOperations | -129.47M | -96.66M | -104.79M | -71.10M |
| PretaxIncome | -129.47M | -96.66M | -104.79M | -71.10M |
| OtherIncomeExpense | 102.00K | -19.00K | -27.00K | -47.00K |
| OtherNonOperatingIncomeExpenses | 102.00K | -19.00K | -27.00K | -47.00K |
| NetNonOperatingInterestIncomeExpense | 12.68M | 8.32M | 2.23M | 442.00K |
| InterestExpenseNonOperating | 0.00 | |||
| InterestIncomeNonOperating | 12.68M | 8.32M | 2.23M | 442.00K |
| OperatingIncome | -142.26M | -104.96M | -106.99M | -71.49M |
| OperatingExpense | 142.26M | 104.96M | 106.99M | 71.49M |
| ResearchAndDevelopment | 124.52M | 86.14M | 82.27M | 51.10M |
| SellingGeneralAndAdministration | 17.74M | 18.82M | 24.71M | 20.39M |
| GeneralAndAdministrativeExpense | 17.74M | 18.82M | 24.71M | 20.39M |
| OtherGandA | 17.74M | 18.82M | 24.71M | 20.39M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 104.33K | |||
| OrdinarySharesNumber | 74.31M | 54.99M | 40.29M | 39.80M |
| ShareIssued | 74.31M | 55.10M | 40.29M | 39.80M |
| TotalDebt | 1.43M | 2.42M | 2.56M | 3.29M |
| TangibleBookValue | 408.96M | 253.90M | 197.55M | 284.57M |
| InvestedCapital | 408.96M | 253.90M | 197.55M | 284.57M |
| WorkingCapital | 396.71M | 244.89M | 192.35M | 281.67M |
| NetTangibleAssets | 408.96M | 253.90M | 197.55M | 284.57M |
| CapitalLeaseObligations | 1.43M | 2.42M | 2.56M | 3.29M |
| CommonStockEquity | 408.96M | 253.90M | 197.55M | 284.57M |
| TotalCapitalization | 408.96M | 253.90M | 197.55M | 284.57M |
| TotalEquityGrossMinorityInterest | 408.96M | 253.90M | 197.55M | 284.57M |
| StockholdersEquity | 408.96M | 253.90M | 197.55M | 284.57M |
| GainsLossesNotAffectingRetainedEarnings | 143.00K | 347.00K | -1.81M | -149.00K |
| OtherEquityAdjustments | 143.00K | 347.00K | -1.81M | -149.00K |
| RetainedEarnings | -435.11M | -305.63M | -208.98M | -104.19M |
| AdditionalPaidInCapital | 843.92M | 559.18M | 408.33M | 388.90M |
| CapitalStock | 6.00K | 4.00K | 3.00K | 3.00K |
| CommonStock | 6.00K | 4.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 42.02M | 23.05M | 18.10M | 11.38M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 257.00K | 1.43M | 1.55M | 2.36M |
| LongTermDebtAndCapitalLeaseObligation | 257.00K | 1.43M | 1.55M | 2.36M |
| LongTermCapitalLeaseObligation | 257.00K | 1.43M | 1.55M | 2.36M |
| CurrentLiabilities | 41.76M | 21.62M | 16.55M | 9.02M |
| OtherCurrentLiabilities | 82.00K | 206.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 1.17M | 988.00K | 1.01M | 931.00K |
| CurrentCapitalLeaseObligation | 1.17M | 988.00K | 1.01M | 931.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.66M | 5.46M | 4.52M | 3.75M |
| PayablesAndAccruedExpenses | 34.92M | 15.17M | 10.93M | 4.13M |
| CurrentAccruedExpenses | 30.42M | 12.40M | 10.49M | 4.02M |
| Payables | 4.50M | 2.77M | 442.00K | 111.00K |
| TotalTaxPayable | 41.00K | 73.00K | 68.00K | 88.00K |
| AccountsPayable | 4.46M | 2.70M | 374.00K | 23.00K |
| TotalAssets | 450.98M | 276.94M | 215.65M | 295.94M |
| TotalNonCurrentAssets | 12.51M | 10.43M | 6.75M | 5.26M |
| OtherNonCurrentAssets | 698.00K | 2.77M | 540.00K | |
| NonCurrentPrepaidAssets | 9.75M | 7.17M | 2.77M | |
| NetPPE | 2.06M | 3.26M | 3.98M | 4.72M |
| AccumulatedDepreciation | -581.00K | -224.00K | ||
| GrossPPE | 2.06M | 3.26M | 3.98M | 4.94M |
| OtherProperties | 2.06M | 3.26M | 3.98M | 4.88M |
| MachineryFurnitureEquipment | 59.00K | 59.00K | ||
| CurrentAssets | 438.47M | 266.51M | 208.90M | 290.69M |
| OtherCurrentAssets | 366.00K | 1.68M | 1.52M | 223.00K |
| PrepaidAssets | 1.90M | 2.35M | 2.64M | 3.31M |
| Receivables | 2.12M | 673.00K | 319.00K | 130.00K |
| AccruedInterestReceivable | 2.12M | 673.00K | 319.00K | 130.00K |
| CashCashEquivalentsAndShortTermInvestments | 434.09M | 261.81M | 204.42M | 287.25M |
| OtherShortTermInvestments | 294.61M | 193.27M | 180.72M | 273.44M |
| CashAndCashEquivalents | 139.48M | 68.54M | 23.70M | 13.81M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -104.51M | -83.73M | -82.43M | -52.27M |
| RepurchaseOfCapitalStock | 0.00 | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 266.29M | 129.74M | 0.00 | 0.00 |
| CapitalExpenditure | -159.00K | -363.00K | -1.57M | |
| EndCashPosition | 139.48M | 68.54M | 23.70M | 13.81M |
| BeginningCashPosition | 68.54M | 23.70M | 13.81M | 338.55M |
| ChangesInCash | 70.94M | 44.84M | 9.89M | -324.74M |
| FinancingCashFlow | 268.82M | 133.41M | 476.00K | 1.39M |
| CashFlowFromContinuingFinancingActivities | 268.82M | 133.41M | 476.00K | 1.39M |
| ProceedsFromStockOptionExercised | 2.53M | 3.68M | 476.00K | 1.39M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockPayments | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 266.29M | 129.74M | 0.00 | 0.00 |
| CommonStockIssuance | 266.29M | 129.74M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -93.53M | -4.85M | 91.48M | -275.44M |
| CashFlowFromContinuingInvestingActivities | -93.53M | -4.85M | 91.48M | -275.44M |
| NetInvestmentPurchaseAndSale | -93.37M | -4.87M | 91.84M | -273.86M |
| SaleOfInvestment | 301.59M | 250.76M | 305.50M | 213.10M |
| PurchaseOfInvestment | -394.96M | -255.62M | -213.66M | -486.97M |
| NetPPEPurchaseAndSale | -159.00K | 14.00K | -363.00K | -1.57M |
| SaleOfPPE | 0.00 | 14.00K | 0.00 | |
| PurchaseOfPPE | -159.00K | 0.00 | -363.00K | -1.57M |
| OperatingCashFlow | -104.35M | -83.73M | -82.06M | -50.69M |
| CashFlowFromContinuingOperatingActivities | -104.35M | -83.73M | -82.06M | -50.69M |
| ChangeInWorkingCapital | 9.16M | -589.00K | 3.02M | 2.83M |
| ChangeInOtherCurrentLiabilities | 10.04M | 1.72M | 5.74M | 3.58M |
| ChangeInOtherCurrentAssets | -2.96M | -5.32M | -1.11M | -30.00K |
| ChangeInPayablesAndAccruedExpense | 2.51M | 2.32M | 351.00K | -683.00K |
| ChangeInPayable | 2.51M | 2.32M | 351.00K | -683.00K |
| ChangeInAccountPayable | 2.51M | 2.32M | 351.00K | -683.00K |
| ChangeInPrepaidAssets | -429.00K | 694.00K | -1.96M | -40.00K |
| OtherNonCashItems | -7.03M | -4.23M | 514.00K | 1.22M |
| StockBasedCompensation | 22.58M | 17.26M | 18.83M | 15.91M |
| AmortizationOfSecurities | -787.00K | 276.00K | ||
| DepreciationAmortizationDepletion | 393.00K | 377.00K | 357.00K | 163.00K |
| DepreciationAndAmortization | 393.00K | 377.00K | 357.00K | 163.00K |
| OperatingGainsLosses | 9.00K | 111.00K | ||
| GainLossOnSaleOfPPE | 9.00K | 111.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -129.47M | -96.66M | -104.79M | -71.10M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OLMA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|